Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis.

1. Gastric damage induced by low-dose aspirin and the protective effect of enteric-coating was assessed in healthy volunteers in a double-blind placebo-controlled cross-over trial using Latin square design. Each was administered placebo, plain aspirin 300 mg daily, plain aspirin 600 mg four times daily, enteric-coated aspirin 300 mg daily, or enteric-coated aspirin 600 mg four times daily for 5 days. Gastric damage was assessed endoscopically, and gastric mucosal bleeding measured. 2. Aspirin 300 mg daily and 600 mg four times daily caused significant increases in gastric injury compared with placebo. Gastric mucosal bleeding was significantly more with the high dose, with a trend towards increased gastric erosions, compared with the low dose. 3. Enteric-coating of aspirin eliminated the injury caused by low dose aspirin and substantially reduced that caused by the higher dose. 4. All dosages and formulations caused similar inhibition of gastric mucosal prostaglandin E2 synthesis. 5. Serum thromboxane levels were suppressed equally with plain and enteric-coated aspirin. 6. In this short-term study in healthy volunteers, gastric toxicity from aspirin was largely topical, independent of inhibition of prostaglandin synthesis, and could be virtually eliminated by the use of an enteric-coated preparation.

[1]  M. Ligumsky,et al.  Rectal administration of nonsteroidal antiinflammatory drugs. Effect on rat gastric ulcerogenicity and prostaglandin E2 synthesis. , 1990, Gastroenterology.

[2]  C. Hawkey,et al.  Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. , 1989, BMJ.

[3]  Final report on the aspirin component of the ongoing Physicians' Health Study. , 1989, The New England journal of medicine.

[4]  M. Langman,et al.  Aspirin and bleeding peptic ulcers in the elderly. , 1988, BMJ.

[5]  G. Tildesley,et al.  Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. , 1988, BMJ.

[6]  D. Graham,et al.  Gastric adaptation: Studies in humans during continuous aspirin administration , 1988 .

[7]  R. Russell,et al.  Peptic ulcer in rheumatoid arthritis. , 1988, Annals of the rheumatic diseases.

[8]  R. Doll,et al.  Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.

[9]  K. McPherson,et al.  Secondary prevention of vascular disease by prolonged antiplatelet treatment , 1988, British medical journal.

[10]  R. Russell,et al.  Peptic ulcer inrheumatoid arthritis , 1988 .

[11]  D. Graham,et al.  Gastric adaptation. Studies in humans during continuous aspirin administration. , 1988, Gastroenterology.

[12]  D. Graham,et al.  Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. , 1987, The American journal of gastroenterology.

[13]  A. Walker,et al.  Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. , 1987, Archives of internal medicine.

[14]  A. Collins,et al.  Upper gastrointestinal findings and faecal occult blood in patients with rheumatic diseases taking nonsteroidal anti-inflammatory drugs. , 1987, British journal of rheumatology.

[15]  A. Blower,et al.  Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. , 1987, Gut.

[16]  B. Strom,et al.  The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. , 1987, Archives of internal medicine.

[17]  M. Langman,et al.  NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND BLEEDING PEPTIC ULCER , 1986, The Lancet.

[18]  D. Graham,et al.  Aspirin and the stomach. , 1986, Annals of internal medicine.

[19]  D. Sitar,et al.  Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets. , 1986, Biopharmaceutics & drug disposition.

[20]  J. C. O'Laughlin,et al.  Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa. , 1982, Gut.

[21]  B. Whittle.  Temporal Relationship Between Cyclooxygenase Inhibition, as Measured by Prostacyclin Biosynthesis, and the Gastrointestinal Damage Induced by Indomethacin in the Rat , 1981 .

[22]  B. Whittle.  Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. , 1981, Gastroenterology.

[23]  R. Nelson,et al.  Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. , 1980, The New England journal of medicine.

[24]  K. Goulston,et al.  Failure of Intravenous Aspirin to Increase Gastrointestinal Blood Loss , 1969, British medical journal.

[25]  M. Grossman,et al.  Fecal blood loss produced by oral and intravenous administration of various salicylates. , 1961, Gastroenterology.